EYPT EYEPOINT INC
2026Q2 · CUSIP 30233G209 · Sector: Healthcare & Biotech
Funds leaving and price falling — historically weak for the next six months
187 funds held EYPT at the end of 2026Q2. Buying is stronger than only 28.4% of US stocks, and the price fell over the same quarter — funds leaving and price weakness at the same time. On the business itself, revenue over the last 12 months was $3M(YoY -94.6%), return on equity is -184.3%. EYPT has had 7 buying rushes in its history, and the price moved +29.4% on average over the six months after (that is the raw price move, not how much it beat the market by). It sits in the Healthcare & Biotech sector.
How many funds owned it, quarter by quarter
Bars = net change in institutional holders, positive (green) or negative (red). Line = total institutional holders.
What happened after each past buying rush 7 times in its history
| Quarter of the rush | How unusual then | Price, next 3 months | Price, next 6 months |
|---|---|---|---|
| 2026Q1 | Top 20% | -53.2% | — |
| 2024Q1 | Top 20% | -32.9% | -22.6% |
| 2023Q4 | Top 20% | -58.2% | -72.0% |
| 2023Q3 | Top 20% | +348.4% | +96.4% |
| 2023Q2 | Top 20% | -53.0% | +111.3% |
| 2021Q4 | Top 20% | -3.1% | +5.5% |
| 2021Q1 | Top 20% | +12.7% | +57.5% |
These are the raw price moves, not how much it beat the market by. Compare them against the market over the same months — in a strong bull market almost everything is up.
Show all the numbers (large funds, value held, options…) ▾ Collapse ▴
These are for people who want to dig. Skip them if they do not mean anything to you — the three numbers above are enough.
Fundamentals
Quarterly figures, revenue up to 10 years back; EPS split-adjusted, early quarters hidden when not calibrable
FCF = operating cash flow − capex, computed from SEC XBRL; banks/insurers have no standard cash-flow structure and are hidden
As of 2026-06-30 · SEC filings (XBRL)
Email me the next update
2026 Q3 holdings are due 2026-11-16. We will email you when the refreshed lists are live.